PureTech Health's CEO and Co-Founder discuss this week's IPF data, the approval of Cobenfy in schizophrenia, and the company's unique hub and spoke business model
Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC
Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more
Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases
Seattle and San Carlos, CA based Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work
Seattle based Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program
Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andrew Scharenberg describes the technical innovations they have come up with to help make it succeed
ASH 2024: France's MaaT Pharma presented early access data at ASH for its microbiome based treatment for GvHD - a formal study will read out early next year
ASH 2024: Nurix Therapeutics' CEO Arthur Sands talks BTK degradation vs inhibition and the company's broader pipeline of degraders
ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future
Neurvati Neurosciences is a Blackstone owned development company that focuses on late stage assets in neuroscience - the first project targets an NMDA subunit, called NR2B, for GRIN disorders
ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
The CEO of Lyndra Therapeutics describes the company's technology that turns daily pills into weekly ones - and potentially longer
ASH 2024: Kura Oncology CEO Troy Wilson highlights combination data in 1L AML for the menin inhibitor ziftomenib
ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets
ASH 2024: Arcellx CEO Rami Elghandour discusses a data update of the iMMagine-1 Study for the company's BCMA CAR-T
ASH 2024: Beam's CEO John Evans on the company's based editing sickle cell data, and preclinical data on a next generation product meant to broaden the potential patient population
ASH 2024: Incyte CEO Hervé Hoppenot on the company's hematology franchise and keeping up the momentum in 2025
ASH 2024: BeiGene CEO John Oyler on degraders, long-term BTK data, BCL2 inhibition, and being a global company
ASH 2024: Autolus CEO Christian Itin talks about the approval of of the CAR-T Aucatzyl, as well as the company's development pipeline (including autoimmune)
.png){kind=logo}
